Indivior eliminates Chief Scientific Officer role; Heidbreder to depart Dec 31, 2026

Indivior Pharmaceuticals, Inc.

CSO position eliminated effective June 1, 2026; Dr. Christian Heidbreder transitions to advisory role through year-end.
Heidbreder's employment terminates Dec 31, 2026 as a termination without cause per existing agreement.
At May 13 annual meeting, shareholders elected all eight director nominees with overwhelming support.
Say-on-pay approved; frequency set to annual until 2032 unless board changes.
Ratification of PwC as independent auditor for fiscal 2026 passed with 99.1M votes for.

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.